Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Exclusion Criteria

• •1. Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
• •2. Intracranial hemorrhage confirmed by imaging.
• •3. Pre-stroke modified Rankin Scale (mRS) score ≥2.
• •4. Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction \<30%.
• •5. History of primary intracerebral hemorrhage.
• •6. History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage).
• •7. Untreated or inadequately treated intracranial aneurysm or vascular malformation.
• •8. Major systemic bleeding within 30 days.
• •9. Active bleeding, including laboratory evidence of coagulopathy (platelet count \<100 × 10⁹/L, activated partial thromboplastin time \>50 seconds, or international normalized ratio \>1.7), or treatment with direct oral anticoagulants within the preceding 48 hours.
• •10. Major surgery within 14 days.
• •11. Persistently elevated blood pressure (systolic \>180 mmHg or diastolic \>110 mmHg) despite treatment.
• •12. Baseline platelet count \<100 × 10⁹/L.
• •13. Severe renal dysfunction (glomerular filtration rate \<30 mL/min or serum creatinine \>220 μmol/L \[2.5 mg/dL\]).
• •14. Known allergy or contraindication to tirofiban or aspirin.
• •15. Current pregnancy or lactation.
• •16. Any intracranial tumor (except asymptomatic meningiomas ≤1.5 cm in diameter).
• •17. Any terminal illness with life expectancy \<6 months.